Amarillo Biosciences, Inc. Share Price Other OTC
Equities
AMAR
US02301P2056
Biotechnology & Medical Research
Sales 2022 | 3.52M 294M | Sales 2023 | 122K 10.18M | Capitalization | 8.32M 694M |
---|---|---|---|---|---|
Net income 2022 | -14M -1.17B | Net income 2023 | -13M -1.08B | EV / Sales 2022 | 3.36 x |
Net cash position 2022 | 585K 48.76M | Net Debt 2023 | 3.81M 318M | EV / Sales 2023 | 99.3 x |
P/E ratio 2022 |
-0.6
x | P/E ratio 2023 |
-0.61
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 45.29% |
Managers | Title | Age | Since |
---|---|---|---|
Chun Hsien Tsai
CEO | Chief Executive Officer | 54 | 15/21/15 |
Lawrence Lin
COO | Chief Operating Officer | 55 | 01/21/01 |
Shu Ying Pan
SAM | Sales & Marketing | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Yao Chung Chiang
BRD | Director/Board Member | 70 | 15/21/15 |
Pao Sheng Wei
BRD | Director/Board Member | 66 | 15/22/15 |
Chung Yi Tsai
BRD | Director/Board Member | 47 | 15/21/15 |
1st Jan change | Capi. | |
---|---|---|
-1.43% | 103B | |
+7.12% | 101B | |
+4.05% | 23.07B | |
-13.07% | 22.23B | |
-4.83% | 18.05B | |
-39.98% | 17.18B | |
-10.93% | 16.94B | |
+6.90% | 14.07B | |
+36.88% | 12.35B |